![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Lineage and Neurgain will collaborate on the clinical testing of Neurgain’s novel Parenchymal Delivery Injection system, OPC1 , which is designed to allow for the administration of cells to the spinal cord without stopping the patient’s respiration.
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lineagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2021
Details:
A new ready-to-inject formulation of OPC1, which enables clinical use at a much larger number of spinal cord treatment centers, accelerating enrollment for a larger and potentially registrational clinical trial.
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
Lineage has strengthened its patent position in order to protect the OPC1 processes, product and composition, and methods of use. Multiple OPC1 batches have been successfully manufactured; GMP production is planned to begin in early 2021.
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020